1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Skin Disease Treatment Technologies and Global Markets

Skin Disease Treatment Technologies and Global Markets

  • December 2015
  • -
  • BCC Research
  • -
  • 128 pages

This BCC Research report provides detailed market, technology and industry analyses to help readers quantify and qualify the market for drugs used in the treatment of the major skin diseases. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2020.

Use this report to:

Assess and quantify current trends in the global dermatology market in the context of size and growth.
Evaluate global market trends for drugs used in the treatment of major skin diseases.
Gain insight into ongoing research into improved treatment modalities, especially those utilizing biological approaches.
Identify long-standing and emerging companies through profiles and an update on M&A activity.

Highlights

The global market for skin disease treatment technologies reached $16.4 billion in 2014 and $17.1 billion in 2015. The market should reach $20.4 billion in 2020, demonstrating a compound annual growth rate (CAGR) of 3.6% from 2015 to 2020.
The U.S market for skin disease treatment dominates the global market throughout the period, and totaled $7.3 billion in 2014. The market should reach $7.5 billion in 2015 and $8.6 billion in 2020 at a CAGR of 2.6% from 2015 to 2020.
BRIC (Brazil, Russia, India, China) is the fastest growing region of the global dermatology market with a CAGR of 6% from 2015 to 2020. The market totaled $3.5 billion in 2015 and should reach more than $4.6 billion by 2020.

STUDY GOALS AND OBJECTIVES

The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for drugs used in the treatment of the major skin diseases. Special emphasis is given to ongoing research into improved treatment modalities, especially those utilizing biological approaches. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2020; these are based on epidemiological data and projections plus information on R&D trends and their likely effects on market potential on a country-by-country basis.


REASONS FOR DOING THE STUDY

The dermatology market is facing a period of change after several years during which it was a relatively modest and slow-growing sector within the overall pharmaceutical environment. The advent of innovative therapies for some skin diseases has been a stimulus for renewed interest in this market among major pharma companies. New contenders in this market have emerged as small- to medium-size companies evolve into medium to large concerns by a process of serial acquisitions. In this environment, there is a need for an up-to-date and comprehensive appraisal of the dermatology marketplace, with a review of the most important diseases, portfolios and pipelines.

SCOPE OF REPORT

This report discusses the implications of the above-mentioned trends in the context of the current size and growth of the dermatology market, discussed both in global terms and in reference to the most important national markets. Long-standing and emerging companies are discussed, with profiles of their leadership and an update on M&A activity. Five-year global sales forecasts are provided for main drug categories, and breakdowns are provided for several national markets.


Table Of Contents

Skin Disease Treatment Technologies and Global Markets
SKIN DISEASE TREATMENT TECHNOLOGIES AND GLOBAL MARKETS
PHM127B
Paul Evers
Project Analyst
CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE OF REPORT 2
MARKET ANALYSES AND FORECASTS 2
METHODOLOGY 2
INTENDED AUDIENCE 3
INFORMATION SOURCES 3
ANALYST'S CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 3
BCC RESEARCH WEBSITE 3
DISCLAIMER 4
CHAPTER 2 SUMMARY 6
SKIN DISEASE AND ITS TREATMENT 6
DISEASES INCLUDED 6
TREATMENTS 6
ABOUT THE MARKET 7
LEADING COMPANIES 7
SUMMARY TABLE GLOBAL MARKET FOR SKIN DISEASE TREATMENT TECHNOLOGIES
BY REGION, THROUGH 2020 ($ MILLIONS) 8
SUMMARY FIGURE GLOBAL MARKET FOR SKIN DISEASE TREATMENT
TECHNOLOGIES BY REGION, 2013-2020 ($ MILLIONS) 8
CHAPTER 3 OVERVIEW 11
SKIN STRUCTURE AND FUNCTIONS 11
STRUCTURE 11
Epidermis 11
Basement Membrane 12
Dermis 12
Hypodermis 12
FUNCTIONS 12
SKIN DISEASES 13
CHAPTER 4 MAJOR SKIN DISEASES 15
DERMATITIS 15
SEBORRHEIC DERMATITIS 15
Available Treatments 15
ATOPIC DERMATITIS, ECZEMA 15
Available Treatments 16
CONTACT DERMATITIS 16
Irritant Contact Dermatitis 17
Available Treatments 17
Allergic Contact Dermatitis 17
Available Treatments 18
DERMATITIS PIPELINE 18
TABLE 1 PRODUCTS UNDERGOING RESEARCH AS POTENTIAL TREATMENTS FOR
DERMATITIS 18
TABLE 2 GLOBAL MARKET FOR DERMATITIS BY TYPE, THROUGH 2020 ($ MILLIONS) 20
IMMUNE-RELATED CONDITIONS 20
LUPUS ERYTHEMATOSUS 20
Treatments Available 21
Pipeline 22
TABLE 3 COMPOUNDS UNDER DEVELOPMENT FOR CUTANEOUS LUPUS TREATMENT 22
IMMUNOBULLOUS DISEASES 22
Treatments Available 23
Market 23
TABLE 4 GLOBAL MARKET FOR IMMUNE-RELATED SKIN DISEASES BY TYPE,
THROUGH 2020 ($ MILLIONS) 23
LICHEN PLANUS 23
Treatments Available 24
ERYTHEMA MULTIFORME 24
Treatments Available 25
PSORIASIS 25
SUBTYPES 25
Plaque Psoriasis 26
Guttate Psoriasis 26
Erythrodermic Psoriasis 26
Pustular Psoriasis 26
Psoriasis of the Nails 26
TREATMENTS AVAILABLE 26
Topical Therapies Available 27
Emollients 27
Keratolytics 27
Topical Corticosteroids 27
Vitamin D3 Products 27
Tazarotene 27
Tar Preparations 27
Anthralin 28
Topical Immunomodulators 28
Intralesional Therapy 28
Phototherapy with UVB 28
Photochemotherapy (PUVA) 28
Systemic Therapy 28
Methotrexate 28
Acitretin 29
Cyclosporine 29
Hydroxyurea 29
Cytokine Antagonists and Other Immunomodulators 29
PSORIASIS TREATMENT BENEFITS AND RISKS 29
MAJOR ENGINEERED PROTEIN TREATMENTS IN USE 30
Etanercept (Enbrel) 30
Adalimumab (Humira) 30
Infliximab (REMICADE) 31
Ustekinumab (STELARA) 31
Alefacept (Amevive) 31
Cost of Treatment 32
TABLE 5 COST OF PSORIASIS THERAPIES IN A TYPICAL WESTERN EUROPEAN
COUNTRY ($) 32
PSORIASIS TREATMENT PIPELINE 32
PSORIASIS TREATMENT MARKET 35
TABLE 6 GLOBAL MARKET FOR PSORIASIS BY REGION, THROUGH 2020 ($
MILLIONS) 36
SKIN INFECTIONS 36
BACTERIAL INFECTIONS 36
Impetigo/Ecthyma 37
Cellulitis 37
Treatments Available 38
Necrotizing Subcutaneous Infection 38
Treatments Available 39
FUNGAL INFECTIONS 39
Candidiasis 39
Treatments Available 40
TABLE 7 ANTIFUNGALS FOR SUPERFICIAL FUNGAL INFECTIONS 40
Tinea Versicolor 41
Treatments Available 41
VIRAL INFECTIONS 42
Herpes Simplex 42
Treatments Available 42
Herpes Zoster 43
Treatments Available 43
Warts 43
Treatments Available 44
TABLE 8 ANTIVIRAL DRUGS AVAILABLE 44
SKIN INFECTION TREATMENT PIPELINE 45
TABLE 9 POTENTIAL DRUG CANDIDATES FOR SKIN INFECTION TREATMENTS 45
ANTI-INFECTIVE MARKET 48
TABLE 10 GLOBAL MARKET FOR SKIN INFECTIONS BY TYPE, THROUGH 2020 ($
MILLIONS) 48
ACNE 48
Comedonal 49
Papulopustular 49
Nodulocystic 49
Treatments Available 49
Retinoids 50
Antibiotics 50
Anti-inflammatory Drugs 51
Hormonal Therapy 51
Treatment Failure 51
ACNE TREATMENT PIPELINE 52
TABLE 11 POTENTIAL PRODUCTS FOR ACNE TREATMENT 52
ACNE TREATMENT MARKET 53
TABLE 12 GLOBAL MARKET FOR ACNE MEDICATIONS BY TYPE, THROUGH 2020 ($
MILLIONS) 53
SKIN CANCERS 54
MELANOMA 54
Treatments Available 54
NONMELANOMA SKIN CANCERS 54
Basal Cell Carcinoma 55
Squamous Cell Carcinoma 55
SKIN CANCER TREATMENT PIPELINE 56
TABLE 13 PRODUCTS IN PIPELINE FOR SKIN CANCER THERAPEUTICS 56
SKIN CANCER TREATMENT MARKET 59
TABLE 14 GLOBAL MARKET FOR SKIN CANCER THERAPEUTICS, THROUGH 2020 ($
MILLIONS) 60
CHAPTER 5 DERMATOLOGY PRODUCTS 62
DESCRIPTIONS 62
CHAPTER 6 CURRENT AND FORECAST MARKETS 78
DEVELOPED MARKETS 78
U.S. 78
TABLE 15 U.S. ANNUAL DIRECT COST OF PRESCRIPTION DRUGS, 2004 ($ MILLIONS) 79
TABLE 16 U.S. MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 79
JAPAN 80
TABLE 17 JAPANESE MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS,
THROUGH 2020 ($ MILLIONS/%) 80
GERMANY 80
TABLE 18 GERMAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 81
FRANCE 81
TABLE 19 FRENCH MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 82
ITALY 82
TABLE 20 ITALIAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 83
SPAIN 83
TABLE 21 SPAIN'S MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 84
UNITED KINGDOM 84
TABLE 22 U.K. MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 86
BRIC MARKETS 86
BRAZIL 86
TABLE 23 BRAZILIAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS,
THROUGH 2020 ($ MILLIONS/%) 87
RUSSIA 87
TABLE 24 RUSSIAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 88
INDIA 88
TABLE 25 INDIA'S MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 89
CHINA 89
TABLE 26 HEALTHCARE STATISTICS IN CHINA, 2006 VERSUS 2011 ($ BILLIONS/%) 90
TABLE 27 CHINESE MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 90
CHAPTER 7 THE DERMATOLOGY INDUSTRY 92
INDUSTRY STRUCTURE AND TRENDS 92
COMPANY PROFILES 94
ABBVIE 94
AGENUS 94
AICURIS GMBH and CO. KG 95
ALLERGAN 96
ALMIRALL 97
AMGEN 98
ANACOR PHARMACEUTICALS INC. 98
ANGES MG 99
APEIRON BIOLOGICS AG 100
ASTELLAS PHARMA INC. 101
ASTION PHARMA A/S 101
ASTRAZENECA 102
BARRIER THERAPEUTICS 103
BASILEA PHARMACEUTICA LTD. 104
BRISTOL-MYERS SQUIBB 104
CELGENE 105
CIPHER PHARMACEUTICALS 105
DUSA PHARMACEUTICALS INC. 106
ELI LILLY 107
GALDERMA PHARMA SA/GALDERMA SA 107
GENENTECH 108
GLAXOSMITHKLINE 109
HANALL BIOPHARMA 109
IMMUNE TECHNOLOGIES and MEDICINE 110
INCYTE 111
JANSSEN BIOTECH 112
KAKEN PHARMACEUTICALS 113
LEO PHARMA A/S 114
MEDA AB 115
NANOBIO 116
NAVIDEA BIOPHARMACEUTICALS 117
NITRIC BIOTHERAPEUTICS 118
NOVARTIS INTERNATIONAL 118
PFIZER 119
PHOTOCURE 120
REGENERON PHARMACEUTICALS INC. 121
STIEFEL, A GSK COMPANY 122
SWITCH BIOTECH 122
VALEANT PHARMACEUTICALS INTERNATIONAL INC. 123
CHAPTER 8 APPENDIX I: GLOSSARY 126
CHAPTER 9 APPENDIX II: THE IMMUNE SYSTEM 132
TWO DEFENSE STRATEGIES 132
HUMORAL IMMUNITY 132
CELLULAR IMMUNITY 132
MARKERS OF SELF 133
HUMORAL IMMUNITY: B LYMPHOCYTES 133
CELLULAR IMMUNITY: T LYMPHOCYTES 134
REGULATORY T CELLS 134
CYTOTOXIC T CELLS 134
NATURAL IMMUNITY 135
TABLE 28 IMMUNOTHERAPEUTICS IN SKIN DISEASES 137
SUMMARY TABLE GLOBAL MARKET FOR SKIN DISEASE TREATMENT TECHNOLOGIES
BY REGION, THROUGH 2020 ($ MILLIONS) 8
TABLE 1 PRODUCTS UNDERGOING RESEARCH AS POTENTIAL TREATMENTS FOR
DERMATITIS 18
TABLE 2 GLOBAL MARKET FOR DERMATITIS BY TYPE, THROUGH 2020 ($ MILLIONS) 20
TABLE 3 COMPOUNDS UNDER DEVELOPMENT FOR CUTANEOUS LUPUS TREATMENT 22
TABLE 4 GLOBAL MARKET FOR IMMUNE-RELATED SKIN DISEASES BY TYPE,
THROUGH 2020 ($ MILLIONS) 23
TABLE 5 COST OF PSORIASIS THERAPIES IN A TYPICAL WESTERN EUROPEAN
COUNTRY ($) 32
TABLE 6 GLOBAL MARKET FOR PSORIASIS BY REGION, THROUGH 2020 ($ MILLIONS) 36
TABLE 7 ANTIFUNGALS FOR SUPERFICIAL FUNGAL INFECTIONS 40
TABLE 8 ANTIVIRAL DRUGS AVAILABLE 44
TABLE 9 POTENTIAL DRUG CANDIDATES FOR SKIN INFECTION TREATMENTS 45
TABLE 10 GLOBAL MARKET FOR SKIN INFECTIONS BY TYPE, THROUGH 2020 ($
MILLIONS) 48
TABLE 11 POTENTIAL PRODUCTS FOR ACNE TREATMENT 52
TABLE 12 GLOBAL MARKET FOR ACNE MEDICATIONS BY TYPE, THROUGH 2020 ($
MILLIONS) 53
TABLE 13 PRODUCTS IN PIPELINE FOR SKIN CANCER THERAPEUTICS 56
TABLE 14 GLOBAL MARKET FOR SKIN CANCER THERAPEUTICS, THROUGH 2020 ($
MILLIONS) 60
TABLE 15 U.S. ANNUAL DIRECT COST OF PRESCRIPTION DRUGS, 2004 ($ MILLIONS) 79
TABLE 16 U.S. MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020
($ MILLIONS/%) 79
TABLE 17 JAPANESE MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 80
TABLE 18 GERMAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 81
TABLE 19 FRENCH MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 82
TABLE 20 ITALIAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 83
TABLE 21 SPAIN'S MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 84
TABLE 22 U.K. MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH 2020
($ MILLIONS/%) 86
TABLE 23 BRAZILIAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS,
THROUGH 2020 ($ MILLIONS/%) 87
TABLE 24 RUSSIAN MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 88
TABLE 25 INDIA'S MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 89
TABLE 26 HEALTHCARE STATISTICS IN CHINA, 2006 VERSUS 2011 ($ BILLIONS/%) 90
TABLE 27 CHINESE MARKET FOR PRESCRIPTION DERMATOLOGY DRUGS, THROUGH
2020 ($ MILLIONS/%) 90
TABLE 28 IMMUNOTHERAPEUTICS IN SKIN DISEASES 137

LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET FOR SKIN DISEASE TREATMENT TECHNOLOGIES
BY REGION, 2013-2020 ($ MILLIONS) 8

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025

  • $ 10 995
  • Industry report
  • May 2016
  • by Global Data

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025 Summary GlobalData estimates sales of Heart Failure (HF) therapeutics to be approximately $3.2B across the 7MM in 2015, encompassing ...

PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • April 2016
  • by Global Data

PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023 Summary Renal cell carcinoma (RCC) is among the 10 most frequently occurring cancers in Western countries. The RCC market ...

OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024

OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024

  • $ 9 495
  • Industry report
  • May 2016
  • by Global Data

OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024 Summary Huntington’s Disease (HD) is a rare, autosomal-dominant, neurodegenerative disorder, characterized by impaired ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.